FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
11/09/2024
Back to search
Official data from USPTO
RETICEP
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
11/09/2024
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
07/27/2022
Registration date
04/23/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/23/2024
Last transaction
04/23/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
JP
Examiner
BULLOFF, TOBY
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Kyoto Drug Discovery & Development Co., Ltd.
Representatives
YAMADA Iichiro
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Ophthalmologic preparations; cardiovascular pharmaceutical preparations; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for the central nervous system; pharmaceutical preparations for orthopaedic purposes; pharmaceutical preparations for use in urology; pharmaceutical preparations for treating respiratory diseases; pharmaceutical agents affecting digestive organs; pharmaceutical preparations for activating cellular function; cytostatics for pharmaceutical purposes
Publications
History of USPTO decisions and trademark events.
24 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/22/2024
FIMP
FINAL DISPOSITION PROCESSED
10/22/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/24/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/23/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/11/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/21/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/21/2024
GPNX
NOTIFICATION PROCESSED BY IB
02/06/2024
PUBO
PUBLISHED FOR OPPOSITION
02/06/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/17/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/17/2024
NPUB
NOTICE OF PUBLICATION
01/17/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/02/2024
RFNT
REFUSAL PROCESSED BY IB
07/22/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/22/2023
RFRR
REFUSAL PROCESSED BY MPU
06/22/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/17/2023
CNSL
SUSPENSION LETTER WRITTEN
05/16/2023
DOCK
ASSIGNED TO EXAMINER
05/15/2023
MAFR
APPLICATION FILING RECEIPT MAILED
09/20/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/16/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
09/15/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/15/2022
Continuous trademark protection
Get notified about every new filing that threatens RETICEP or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.